---
title: "BCAX.US (BCAX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BCAX.US/news.md"
symbol: "BCAX.US"
name: "BCAX.US"
parent: "https://longbridge.com/en/quote/BCAX.US.md"
datetime: "2026-05-20T08:50:51.120Z"
locales:
  - [en](https://longbridge.com/en/quote/BCAX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BCAX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BCAX.US/news.md)
---

# BCAX.US (BCAX.US) — Related News

### [Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data](https://longbridge.com/en/news/286469142.md)
*2026-05-14T21:09:08.000Z*
> Bicara Therapeutics (NASDAQ: BCAX) announced that its lead cancer drug candidate, ficerafusp alfa, is on track for pivot

### [Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)](https://longbridge.com/en/news/286216781.md)
*2026-05-13T07:35:16.000Z*
> Wedbush analyst has maintained a Buy rating on Bicara Therapeutics Inc. (BCAX) with a price target of $30.00, while the 

### [Bicara Therapeutics hires Replimune, Sanofi alum as CCO](https://longbridge.com/en/news/286089758.md)
*2026-05-12T11:26:22.000Z*
> Bicara Therapeutics has appointed Chris Sarchi as its chief commercial officer as it prepares for a potential accelerate

### [Bicara Records $56 Mln Loss In Q1; Provides Updates On Ficerafusp Alfa Trials](https://longbridge.com/en/news/285962118.md)
*2026-05-11T14:40:18.000Z*
> Bicara Therapeutics Inc. (BCAX) reported a net loss of $56.21 million for Q1 2026, compared to a loss of $36.85 million 

### [](https://longbridge.com/en/news/285945797.md)
*2026-05-11T12:40:21.000Z*
> Bicara Therapeutics shares are trading lower. The company reported worse-than-expected Q1 EPS results.

### [Bicara Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285934017.md)
*2026-05-11T11:35:00.000Z*
### [Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday](https://longbridge.com/en/news/285240303.md)
*2026-05-05T16:35:45.000Z*
> Bicara Therapeutics (NASDAQ:BCAX) is set to announce its Q1 2026 earnings on May 12, with analysts expecting a loss of $